These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 16612846)
1. [Buprenorphine matrix patch well tolerated. The challenge of tumor pain]. MMW Fortschr Med; 2006 Jan; 148(1-2):42-3. PubMed ID: 16612846 [No Abstract] [Full Text] [Related]
2. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
3. Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936 [TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
5. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
6. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Barutell C; Camba A; González-Escalada JR; Rodríguez M; Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364 [TBL] [Abstract][Full Text] [Related]
7. Allergic contact dermatitis due to transdermal buprenorphine. Pérez-Pérez L; Cabanillas M; Loureiro M; Fernández-Redondo V; Labandeira J; Toribio J Contact Dermatitis; 2008 May; 58(5):310-2. PubMed ID: 18416765 [No Abstract] [Full Text] [Related]
8. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474 [TBL] [Abstract][Full Text] [Related]
10. Buprenorphine TDS: the clinical development rationale and results. Radbruch L; Vielvoye-Kerkmeer A Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119 [TBL] [Abstract][Full Text] [Related]
11. Buprenorphine and the transdermal system: the ideal match in pain management. Budd K Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine]. Schutter U; Ritzdorf I; Heckes B MMW Fortschr Med; 2008 Jun; 150 Suppl 2():96-103. PubMed ID: 18712130 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. James IG; O'Brien CM; McDonald CJ J Pain Symptom Manage; 2010 Aug; 40(2):266-78. PubMed ID: 20541900 [TBL] [Abstract][Full Text] [Related]
14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
15. [Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group]. Greco MT; Deandrea S; Corli O; Montanari M; Caraceni A; Apolone G; Recenti Prog Med; 2008 Nov; 99(11):538-51. PubMed ID: 19209537 [TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland. Przeklasa-Muszynska A; Dobrogowski J Curr Med Res Opin; 2011 Jun; 27(6):1109-17. PubMed ID: 21456888 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Ruggiero A; Coccia P; Arena R; Maurizi P; Battista A; Ridola V; Attinà G; Riccardi R Pediatr Blood Cancer; 2013 Mar; 60(3):433-7. PubMed ID: 23034996 [TBL] [Abstract][Full Text] [Related]
18. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Kress HG Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516 [TBL] [Abstract][Full Text] [Related]
19. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies. Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068 [TBL] [Abstract][Full Text] [Related]
20. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Likar R; Krainer B; Sittl R Int J Clin Pract; 2008 Jan; 62(1):152-6. PubMed ID: 18173815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]